MAPK3 and Dyskinesia: These previous studies [28,29,30] suggested that the effects of statins on LID were related to a reduction in the activation of Ras-extracellular signal-regulated kinase (ERK1/2), a molecular pathway essential in the pathophysiology associated with dyskinesia [42,43], rather than with cholesterol-dependent effects.